|
MFSD9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.56128451781024E-13 |
| Normal-vs-Stage2 |
1.15770000030935E-07 |
| Normal-vs-Stage3 |
6.14286399525099E-13 |
| Normal-vs-Stage4 |
2.99371638590173E-12 |
| Stage1-vs-Stage2 |
8.590600E-01 |
| Stage1-vs-Stage3 |
3.362300E-02 |
| Stage1-vs-Stage4 |
3.278500E-02 |
| Stage2-vs-Stage3 |
1.075170E-01 |
| Stage2-vs-Stage4 |
5.515700E-02 |
| Stage3-vs-Stage4 |
4.503400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.99200722162641E-16 |
| Normal-vs-AfricanAmerican |
2.68750000032014E-08 |
| Normal-vs-Asian |
1.95619964671323E-10 |
| Caucasian-vs-AfricanAmerican |
7.872200E-01 |
| Caucasian-vs-Asian |
4.401200E-01 |
| AfricanAmerican-vs-Asian |
7.550600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.295763827462E-14 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
1.732160E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.3429035661261E-11 |
| Normal-vs-Age(41-60Yrs) |
1.88737914186277E-15 |
| Normal-vs-Age(61-80Yrs) |
1.64590563400679E-12 |
| Normal-vs-Age(81-100Yrs) |
4.237200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.366400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.405200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.128600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.118200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.893600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.651800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.417300E-03 |
| Classical-VS-Follicular |
5.639000E-01 |
| Classical-VS-Other |
3.158400E-01 |
| Classical-VS-Normal |
1.62792002100787E-12 |
| Tall-VS-Follicular |
6.287500E-02 |
| Tall-VS-Other |
9.207600E-01 |
| Tall-VS-Normal |
1.27198251931304E-12 |
| Follicular-VS-Other |
4.949000E-01 |
| Follicular-VS-Normal |
5.24600030082922E-10 |
| Other-VS-Normal |
5.770100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.50750547997814E-14 |
| Normal-vs-N1 |
9.99200722162641E-14 |
| N0-vs-N1 |
1.259560E-02 |
|
|
